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Summary:
The number of CD34 þ cells infused into patients at the time of autologous or allogeneic transplantation is a clinically important variable, but the viability of these cells has not been extensively documented. In this study, we analyzed the recovery of viable CD34
þ cells before and after cryopreservation on 79 autologous stem cell products, using a novel flow cytometry assay without red cell lysis. For 70 PBSC harvest samples, the mean viable / kg) after thawing. The median recovery was 93% (range 48-107%), with 90% recovery for NHL (range 48-100%, n ¼ 34), 83% for multiple myeloma (range 56-106%, n ¼ 11), 92.3% for acute leukemia (range 71-100% n ¼ 7) and 94.5% for nonhematological malignancies (range 50-107% n ¼ 18). Similarly, for autologous bone marrows (n ¼ 9) the median recovery of viable CD34 þ cells was 90% (range 68-100%). The recovery of viable CD34 þ cells/kg in PBSC harvests has been associated with adequate engraftment, but accelerated reconstitution has been observed with higher cell doses. [2] [3] [4] [5] [6] [7] In the setting of autologous transplantation, nearly all patients receive cryopreserved cells. Cryopreservation is associated with variable loss of cell viability and a reduction in the absolute number of viable CD34 þ cells available for reinfusion.
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Guidelines published by the International Society for Hematotherapy and Graft Engineering (ISHAGE) were a significant move towards the standardization of the CD34 assay. [8] [9] [10] [11] [12] However, methods for establishing the viability of CD34 þ cells post-cryopreservation have proved more difficult to establish, due to the presence of cellular fragmentation and debris, increased apoptosis and cell death, and the effects of DMSO and red cell lysing agent on thawed samples with time.
To date all methods described for CD34 þ cell enumeration rely on a red cell lysis procedure that may have detrimental effects on the viability of the CD34 þ cells with time. Various groups have reported the recovery of viable CD34 þ cells post thawing. 1, [13] [14] [15] [16] [17] In all cases the thawed product was manipulated, either by washing 1 or diluting in PBS, 17 potentially resulting in nonspecific loss of CD34 þ cells and thus not reflecting the actual number of viable CD34 þ cells available for transplant. Ultimately, the enumeration of viable CD34 þ cells for reinfusion is likely to be a clinically important variable to predict graft success or failure.
In this report, we introduce a novel flow cytometry protocol that can reliably enumerate viable CD34 þ cells in thawed stem cell products. This may enable identification of patients at risk of poor hematological recovery, who may benefit from further stem cell collections.
Materials and methods

Patient samples
Samples were taken from adult and pediatric patients undergoing autologous or allogeneic transplantation for hematological malignancies with informed consent. The initial validation protocol compared the dual platform CD34 assay (according to ISHAGE guidelines) 12, 18 to an in-house method not using red cell lysis. Freshly collected samples for analysis consisted of seven peripheral blood (PB) samples from patients mobilized with G-CSF and chemotherapy, 18 PBSC harvests from 10 autologous patients and three allogeneic bone marrows (BM).
The recovery of viable CD34 þ cells was directly compared before cryopreservation and after thawing on a total of 70 autologous PBSC products and nine autologous BM harvests. The stem cell products were collected from 34 patients diagnosed with non-Hodgkin's lymphoma (NHL), 11 with multiple myeloma (MM), seven with acute leukemia and 18 patients with nonhematological malignancies.
Cryopreservation and processing of hemopoietic stem cell products PB stem cell products and BM samples were either processed immediately after collection or stored overnight at 41C. In all, 100 ml of autologous plasma was added to stored PBSCH products when the WCC exceeded 250 Â 10 9 /l. Before freezing, the PBSCH products and BM samples were processed by centrifugation or on a Cobe 2991 (Gambro, USA) to remove either excess plasma or red blood cells, respectively. All products were concentrated to a mean cell concentration of 200-400 Â 10 6 /ml and mixed with DMSO to a final concentration of 10%. Aliquots of 0.5 ml of the HPC concentrates were transferred to small pilot vials and were frozen with HPC bags to À801C in a controlled rate programmed freezer (Planer Cryo 10) at a controlled rate of À11C/min to À801C, or dump frozen in an À801C freezer overnight (where the typical freezing kinetics are À31C/min to À801C). The HPCs and pilot vials were transferred to liquid nitrogen storage tanks until the day of reinfusion.
At thawing a small pilot vial was removed from the liquid nitrogen storage container, immediately placed in a water bath at 371C, gently shaken and removed when only a few ice crystals were left (this method is also applied to the thawing of HPC bags). When the sample was completely thawed and well mixed, a 10 ml aliquot was stained according to the no-lyse protocol.
In-house no-lyse single platform protocol For fresh samples, 50 ml of blood (obtained by reverse pipetting) or HPC product was stained with 5 ml of CD34 PE, 5 ml CD45 FITC and 10 ml of 7-AAD in a TRU-COUNT tube (all reagents were titred in-house and supplied by BD Bioscience, San Jose, CA, USA) and incubated for 15 min at room temperature. No wash steps or lysis agent was used in the procedure. PBS 500 ml was added to the tube immediately prior to the analysis by flow cytometry.
For thawed HPC products 10 ml of the sample (obtained from pilot vial) was stained as described above. In addition, post thaw samples were neither washed to remove DMSO nor diluted to achieve the desired cell count, to minimize potential errors. However, timing is critical with thawed samples and acquisition was performed within 30 min of thawing.
Flow cytometry
List mode data were acquired on a FACSCalibur flow cytometer and analyzed using Cell Quest 3.1. software (BD Bioscience, San Jose, CA, USA). The original dual platform ISHAGE gating strategy and calculation described by Keeney and Co-workers 11, 12 was used to obtain the number of CD34 þ cells per micro liter. This is the standard protocol used in our institution and therefore used as the reference method. Total WCC was obtained from an Advia 120 (Bayer) hematology analyzer.
Gating strategy for the in-house no-lyse single platform protocol Figure 1 shows the gating strategy for CD34 analysis on a thawed PBSCH product, using the in-house no-lysis protocol (for BM samples a broader forward and side scatter gate is required, as BM progenitor cells display a heterogeneous CD34 expression), which is similar to the ISHAGE analysis protocol with the following modifications. FL1 threshold was set on CD45 expression ( Figure 1a ). Viable leukocytes were identified as 7-AAD negative events (Figure 1b) . TRUCOUNT beads were enumerated in R7 (Figure 1(g) . Acquisition ceased when a minimum of 100 CD34 þ events and 3000 beads were collected. The number of CD34 þ cells per micro liter was calculated as follows: 
Statistical analysis
All statistical analysis was performed using Excel 97 software (Microsoft, Redmond A). Figure 2 shows the linear correlation of the absolute CD34 þ cell counts for 28 fresh samples (consisting of seven PB samples, 18 PBSCHs and three BMs) analyzed by the single platform viable CD34 assay and the dual platform ISHAGE protocol. Absolute numbers of CD34 þ cells ranged from 7.6 to 21 923/ml. There was no significant difference between the median CD34 þ cells per micro liter obtained for the two methods, with the viable CD34 assay showing a median of 736/ml, compared to a median of 728/ ml for the dual platform ISHAGE method (P ¼ 0.98). The two methods showed excellent correlation (R 2 ¼ 0.9989, slope ¼ 1.0, and intercept ¼ 0).
Results
Comparison of CD34 protocols
A lysis step was not used, as a significant reduction in the viability of thawed CD34 þ cells was observed within 15 min of the addition of the lysing agent. For samples without lyse the mean CD34% was 1.75 (range 0.14-4.03%) compared to a mean 1.37% (range 0.11-3.6%) with lyse for 10 thawed samples. This represents an average loss Figure 3 compares the difference in the absolute number of CD34 þ cells when either 10 000 beads or 3000 beads were acquired. In all, 20 samples from fresh PBSC harvests were analyzed by the viable CD34 assay. The results show no significant difference in the number of CD34 þ cells (P ¼ 0.99) and for all subsequent assays a minimum of 3000 beads were acquired.
Comparison of bead count
Enumeration of viable CD34
þ cells in thawed products 6 /kg). The median recovery was 93% (range 48-107%). Further analysis showed a median recovery of 90% for NHL (range 48-100%, n ¼ 34), 83% for MM (range 56-106%, n ¼ 11), 92.3% for acute leukemia (range 71-100% n ¼ 7) and 94.5% for nonhematological malignancies (range 50-107% n ¼ 18). There was no significant difference in the recovery of viable CD34 þ cells between the four groups (P40.17 for all groups tested, Figure 4) . Six patients showed recovery of o60% viable CD34 þ cells from thawed autologous PBSC products, without any obvious explanation for these losses.
Similarly, autologous BM collections (n ¼ 9) also showed a good recovery of viable CD34 We also compared the recovery of viable CD34 þ cells post thaw between adult and pediatric stem cell collections. The median recovery of viable CD34 þ cells from 51 adult stem cell products post thaw was 91% (range 48-106%), compared to a median recovery of 94% (range 50-107%) viable CD34 þ cells from 28 pediatric stem cell products ( Figure 5, P ¼ 1.06) .
We also assessed the number of viable CD34 þ cells using two different forms of freezing, that is, controlled rate programmed freezing and dump freezing in a minus 80 freezer. The median recovery of viable CD34 þ cells was 93% (n ¼ 60) for rate-controlled frozen samples and 86.7% (n ¼ 15) for dump frozen samples (P ¼ 0.106). þ cells (range 48-106%, n ¼ 51), compared to 94% (range 50-107%, n ¼ 28) for pediatric HPC products, P ¼ 1.06). , had platelet recovery on day 39.
Discussion
In this study, we describe a simple CD34 þ cell counting protocol that is suitable for fresh and post thaw HSC products. This method is novel as it does not require the use of a red cell lysing agent, dilution of the thawed product, or centrifugation. Commercial kits that are available for the single platform enumeration of CD34 þ cells rely on the addition of a lysing agent. 8, 9, 18 These kits are not suitable for thawed HSC products, as we have shown a significant reduction (P ¼ 0.001) in the viability of thawed CD34 þ cells occurring within 15 min of the addition of lysing agent. To minimize the number of variables and improve the accuracy of our method, thawed samples were not washed to remove DMSO, as this can lead to nonspecific cell loss. Similarly, samples were not diluted prior to labeling as this can introduce errors in pipetting and volume calculations, and further cell loss due to centrifugation.
Some studies have shown that inter and intravariability of absolute CD34 þ cell counts can be reduced by the adoption of single platform counting methods. [19] [20] [21] [22] Various microsphere bead products are currently available for single platform absolute counting, as either beads suspended in liquid medium, or as lyophilized pellets. However, a number of limitations exist when using liquid-phase beads for absolute counting, including the need for thorough mixing before sampling, and the extra pipetting step involved in adding beads to the sample. 19, 22, 23 Lyophilized bead preparations have been shown to have less inherent errors when used for absolute counting. 19, 22 The inclusion of a viability dye allows the direct measurement of viable CD34 þ cells. 7-AAD was chosen as it is a reliable marker for dead cells, is readily available and can be added directly to the cell suspension during the incubation period with monoclonal antibodies. Other viability dyes such as Syto16 and AnnexinV are markers of early apoptosis and may underestimate the number of viable CD34 þ cells within samples. 13, 15, 16 The yield of CD34 þ cells was directly compared before and after cryopreservation. The overall median recovery of viable CD34 þ cells post thaw was 93%. Some patients (7.5%) had recovery of o60% viable CD34 þ cells from thawed stem cell products. However, all transplanted patients (n ¼ 29) received X1.8 Â 10 6 viable CD34 þ cells/ kg. The wide variation in CD34 recovery may reflect differences in patient characteristics, such as number and type of treatment protocols. Traditionally, evaluation of PBSC harvests after thawing was performed by Trypan blue exclusion, with viabilities typically 80% or higher for the total population, but this method fails to identify the viability of rare cells such as CD34 þ cells. Similarly, colony assays were once routinely performed to assess the function of hemopoietic progenitors post-cryopreservation, but these assays are labor intensive, have poor reproducibility, and results are not available for 2 weeks. 5, 24 Colony assays also fail to reflect the long-term repopulating capacity of the hemopoietic stem cell and hence have never correlated well with hematological recovery.
To ensure rapid engraftment, a threshold of 2 Â 10 6 CD34 þ cell/kg has been identified as the target number needed at the time of harvest, but it is unclear what minimum number is needed at the time of reinfusion. Our data do not identify a lower threshold of viable CD34 þ cells needed to ensure successful engraftment, and study of further cases around the threshold value of 2 Â 10 6 /kg, would be needed to further assess this issue.
In conclusion, cryopreservation of stem cell products results in an overall loss of viable CD34 þ cells. This loss is variable and cannot be determined by conventional assays. Applying our novel CD34 assay may identify patients at risk of poor hematological recovery that could benefit from further stem cell collections. This assay offers a new approach for a more informative determination of the number of viable CD34
þ cells in stem cell products and is capable of achieving standardization in clinical laboratories.
